The combination of volumetric arc radiation therapy and boost high-dose rate interstitial brachytherapy for T3N2c tongue cancer: a technical report-Reference-Cited by-同舟云学术

The combination of volumetric arc radiation therapy and boost high-dose rate interstitial brachytherapy for T3N2c tongue cancer: a technical report

Published:2022-10-13 Issue:1 Volume:53 Page:85-90
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Murakami Naoya¹^ORCID,Sakuramachi Madoka¹,Kashihara Tairo¹,Chiba Takahito²,Nakamura Satoshi²,Ono Keisuke³,Ueno Takao⁴,Yoshimoto Seiichi⁵^ORCID,Yoshida Ken⁶,Masui Koji⁷,Akiyama Hironori⁸,Igaki Hiroshi¹^ORCID

Affiliation:

1. National Cancer Center Hospital Department of Radiation Oncology, , Tokyo, Japan

2. National Cancer Center Hospital Radiation Safety and Quality Assurance Division, , Tokyo, Japan

3. Tokyo Dental College, Suidobashi Hospital Department of Oral and Maxillofacial Surgery, , Tokyo, Japan

4. National Cancer Center Hospital Department of Oral Health and Diagnostic Sciences, , Tokyo, Japan

5. National Cancer Center Hospital Department of Head and Neck Surgery, , Tokyo, Japan

6. Kansai Medical University Department of Radiology, , Osaka, Japan

7. Kyoto Prefectural University of Medicine Graduate School of Medical Science Department of Radiology, , Kyoto, Japan

8. Osaka Dental University Department of Oral Radiology, , Osaka, Japan

Abstract

Abstract Currently, tongue cancers are primarily managed by surgery, and interstitial brachytherapy is only recommended for a selected group of early state T1-2N0 patients who refuse surgery or are medically inoperable. In this report, a case with T3N2cM0 tongue cancer who has been effectively treated by the combination of concurrent chemoradiotherapy involving volumetric arc therapy and boost high-dose rate interstitial brachytherapy is presented. Of course, surgery remains the main treatment strategy for tongue cancer patients; however, the authors believe that if volumetric arc therapy is carefully planned to reduce the mandible dose as much as possible and high-dose rate interstitial brachytherapy with a mouthpiece that protects the mandible is combined, it is possible to treat T3N2 disease, and this can be considered for patients who want to preserve organ function.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://academic.oup.com/jjco/article-pdf/53/1/85/48519930/hyac160.pdf

Reference22 articles.

1. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation;Pernot;Otolaryngol Head Neck Surg,1996

2. Complications following definitive irradiation for cancers of the oral cavity and the oropharynx (in a series of 1134 patients);Pernot;Int J Radiat Oncol Biol Phys,1997

3. Head and neck cancer: an evolving treatment paradigm;Cognetti;Cancer,2008

4. Experience of intentional internal high-dose policy volumetric modulated arc therapy of neck lymph node metastasis ≧ 2 cm in patients with head and neck squamous cell carcinoma;Front Oncol,2021